Infections after hematopoietic stem cell transplantation: Difference between revisions
From IDWiki
m (→: typo) |
(added up to EBV) |
||
| Line 31: | Line 31: | ||
| |
| |
||
| |
| |
||
|} |
|||
==Prevention== |
|||
{| class="wikitable" |
|||
! Infection |
|||
! Preventing exposure |
|||
! Preventing disease |
|||
|- |
|||
! colspan=3 | Bacterial infections |
|||
|- |
|||
| Early disease (0-100 days after HCT) |
|||
| |
|||
| Use [[levofloxacin]] or other respiratory fluoroquinolone in adult patients with anticipated neutropenia of 7 or more days until recovery of neutropenia. GM-CSF or G-CSF may decrease risk of infection, but unclear if it decreases mortality. |
|||
|- |
|||
| Late disease (100 days after HCT) |
|||
| |
|||
| Antibiotic prophylaxis is indicated for alloHSCT recipients with [[chronic GVHD]] to prevent invasive [[pneumococcal]] disease until cGVHD resolves. |
|||
|- |
|||
| [[CLABSI]] |
|||
| Implement a CLABSI bundle to ensure maximum sterility on insertion. |
|||
| If infection rate is still >1 per 1000 catheter days, can consider prophylactic [[minocycline]] plus [[rifampin]]. |
|||
|- |
|||
| ''[[Streptococcus pneumoniae]]'' |
|||
| Routine precautions. |
|||
| Immunization for all HCT recipients. Antibiotic prophylaxis for [[chronic GVHD]] and for low IgG levels, regardless of vaccination status, usually with [[penicillin]]. |
|||
|- |
|||
| [[Viridans group streptococci]] |
|||
| |
|||
| Pre-conditioning dental consults. |
|||
|- |
|||
| ''[[Haemophilus influenzae]]'' type b |
|||
| Ensuring up-to-date immunizations of close contacts. |
|||
| Immunization of all HCT recipients. Post-exposure prophylaxis if exposed. |
|||
|- |
|||
| ''[[Bordatella pertussis]]'' |
|||
| Ensuring up-to-date immunizations of close contacts. |
|||
| Immunization of all HCT recipients. Post-exposure prophylaxis if exposed. |
|||
|- |
|||
! colspan=3 | Viral infections |
|||
|- |
|||
| [[Cytomegalovirus]] |
|||
| Pre-transplant screening of donor and recipient serostatus. |
|||
| All R+ or D+ recipients should have either prophylaxis or close monitoring with preemptive treatment until at least day 100. Monitoring should start on day 10 and continue weekly until at least day 100. |
|||
|- |
|||
| [[Epstein-Barr virus]], especially PTLD |
|||
| Pre-transplant screening of donor and recipient serostatus, especially in children. |
|||
| Monitor high-risk recipients (T-cell depletion, ant-T-cell antibodies, umbilical cord transplants, and haplo-identical transplants), with reduction in immunosuppression if rising viral load. |
|||
|} |
|} |
||
Revision as of 19:43, 17 May 2020
Timeline of Infections
| Time | Risk factors | Bacteria | Viruses | Fungi | Parasites |
|---|---|---|---|---|---|
| Pre-engraftment day 0 to 30 |
Neutropenia, mucositis, and central lines | GPCs and GNBs | BK virus, HSV, and resp/enteric viruses | Candida and Aspergillus | Strongyloides |
| Early post-engraftment to day 100 |
Immunosuppressing meds, acute GVHD, central lines | GPCs, encapsulated bacteria, Listeria, Salmonella, Nocardia | HSV, CMV, HHV-6, adenovirus, resp/enteric viruses | Aspergillus, other molds, PJP | Strongyloides, Toxoplasma |
| Mid post-engraftment to 1 year |
Immunosuppressing meds, chronic GVHD | Encapsulated bacteria, Listeria, Salmonella, Nocardia | VZV, EBV (and PTLD), CMV, respiratory/enteric viruses | Aspergillus, other molds, PJP | |
| Late post-engraftment after 1 year |
Immunosuppresing meds, chronic GVHD | Encapsulated bacteria, Listeria, Salmonella, Nocardia | VZV, CMV, respiratory/enteric viruses |
Prevention
| Infection | Preventing exposure | Preventing disease |
|---|---|---|
| Bacterial infections | ||
| Early disease (0-100 days after HCT) | Use levofloxacin or other respiratory fluoroquinolone in adult patients with anticipated neutropenia of 7 or more days until recovery of neutropenia. GM-CSF or G-CSF may decrease risk of infection, but unclear if it decreases mortality. | |
| Late disease (100 days after HCT) | Antibiotic prophylaxis is indicated for alloHSCT recipients with chronic GVHD to prevent invasive pneumococcal disease until cGVHD resolves. | |
| CLABSI | Implement a CLABSI bundle to ensure maximum sterility on insertion. | If infection rate is still >1 per 1000 catheter days, can consider prophylactic minocycline plus rifampin. |
| Streptococcus pneumoniae | Routine precautions. | Immunization for all HCT recipients. Antibiotic prophylaxis for chronic GVHD and for low IgG levels, regardless of vaccination status, usually with penicillin. |
| Viridans group streptococci | Pre-conditioning dental consults. | |
| Haemophilus influenzae type b | Ensuring up-to-date immunizations of close contacts. | Immunization of all HCT recipients. Post-exposure prophylaxis if exposed. |
| Bordatella pertussis | Ensuring up-to-date immunizations of close contacts. | Immunization of all HCT recipients. Post-exposure prophylaxis if exposed. |
| Viral infections | ||
| Cytomegalovirus | Pre-transplant screening of donor and recipient serostatus. | All R+ or D+ recipients should have either prophylaxis or close monitoring with preemptive treatment until at least day 100. Monitoring should start on day 10 and continue weekly until at least day 100. |
| Epstein-Barr virus, especially PTLD | Pre-transplant screening of donor and recipient serostatus, especially in children. | Monitor high-risk recipients (T-cell depletion, ant-T-cell antibodies, umbilical cord transplants, and haplo-identical transplants), with reduction in immunosuppression if rising viral load. |
Further Reading
- Life-threatening Infection in Transplant Recipients. Crit Care Clin. 2013 Oct;29(4):953-73. doi: 10.1016/j.ccc.2013.06.012
